Your browser doesn't support javascript.
loading
Variants in IGLL1 cause a broad phenotype from agammaglobulinemia to transient hypogammaglobulinemia.
Soomann, Maarja; Bily, Viktor; Elgizouli, Magdeldin; Kraemer, Dennis; Akgül, Gülfirde; von Bernuth, Horst; Bloomfield, Markéta; Brodszki, Nicholas; Candotti, Fabio; Förster-Waldl, Elisabeth; Freiberger, Tomas; Gizewska, Maria; Klocperk, Adam; Kölsch, Uwe; Nichols, Kim E; Krüger, Renate; Oak, Ninad; Pac, Malgorzata; Prader, Seraina; Schmiegelow, Kjeld; Sedivá, Anna; Sogkas, Georgios; Stittrich, Anna; Stoltze, Ulrik Kristoffer; Theodoropoulou, Katerina; Wadt, Karin; Wong, Melanie; Zeyda, Maximillian; Pachlopnik Schmid, Jana; Trück, Johannes.
Afiliação
  • Soomann M; Division of Immunology and the Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: Maarja.Soomann@kispi.uzh.ch.
  • Bily V; Molecular Genetics Laboratory, Centre for Cardiovascular Surgery and Transplantation Brno and Medical Faculty, Masaryk University, Brno, Czechia.
  • Elgizouli M; Institute of Medical Genetics, University of Zurich, Zurich, Switzerland.
  • Kraemer D; Institute of Medical Genetics, University of Zurich, Zurich, Switzerland.
  • Akgül G; Institute of Medical Genetics, University of Zurich, Zurich, Switzerland.
  • von Bernuth H; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine, University Hospital Center, Berlin, Germany; Berlin Institute of Health at Charité-Universitätsmediz
  • Bloomfield M; Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, Prague, Czechia.
  • Brodszki N; Childrens' Hospital, Skåne University Hospital, Lund, Sweden.
  • Candotti F; Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Förster-Waldl E; Department of Paediatrics and Adolescent Medicine, Division of Neonatology, Neuropaediatrics, and Paediatric Intensive Care and Center for Congenital Immunodeficiencies and Jeffrey Modell Diagnostic & Research Center, Medical University of Vienna, Vienna, Austria.
  • Freiberger T; Molecular Genetics Laboratory, Centre for Cardiovascular Surgery and Transplantation Brno and Medical Faculty, Masaryk University, Brno, Czechia.
  • Gizewska M; Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases, and Cardiology of the Developmental Age, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Klocperk A; Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, Prague, Czechia.
  • Kölsch U; Department of Immunology, Labor Berlin-Charité Vivantes GmbH, Berlin, Germany.
  • Nichols KE; Department of Oncology, St Jude Children's Research Hospital, Memphis, Tenn.
  • Krüger R; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine, University Hospital Center, Berlin, Germany.
  • Oak N; Department of Oncology, St Jude Children's Research Hospital, Memphis, Tenn.
  • Pac M; Department of Immunology, The Children's Memorial Health Institute, Warsaw, Poland.
  • Prader S; Division of Immunology and the Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Schmiegelow K; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Sedivá A; Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, Prague, Czechia.
  • Sogkas G; Department of Rheumatology and Immunology, Hannover Medical University, and Hannover Medical School, Hannover, Germany.
  • Stittrich A; Department of Human Genetics, Labor Berlin-Charité Vivantes GmbH, Berlin, Germany.
  • Stoltze UK; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Theodoropoulou K; Unit of Pediatric Immunology, Allergology and Rheumatology, Department of Woman, Mother, Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Wadt K; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Genetics, University Hospital Copenhagen, Copenhagen, Denmark.
  • Wong M; Department of Allergy and Immunology, The Children's Hospital at Westmead, Sydney, Australia.
  • Zeyda M; Department of Pediatrics and Adolescent Medicine, Austrian Newborn Screening, Clinical Division of Pediatric Pulmonology, Allergology and Endocrinology, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.
  • Pachlopnik Schmid J; Division of Immunology and the Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Trück J; Division of Immunology and the Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Article em En | MEDLINE | ID: mdl-39147326
ABSTRACT

BACKGROUND:

Agammaglobulinemia due to variants in IGLL1 has traditionally been considered an exceedingly rare form of severe B-cell deficiency, with only 8 documented cases in the literature. Surprisingly, the first agammaglobulinemic patient identified by newborn screening (NBS) through quantification of kappa-deleting recombination excision circles harbored variants in IGLL1.

OBJECTIVE:

We comprehensively reviewed clinical and immunologic findings of patients with B-cell deficiency attributed to variants in IGLL1.

METHODS:

NBS programs reporting the use of kappa-deleting recombination excision circle assays, the European Society for Immunodeficiencies Registry, and authors of published reports featuring patients with B-cell deficiency linked to IGLL1 variants were contacted. Only patients with (likely) pathogenic variants, reduced CD19+ counts, and no alternative diagnosis were included.

RESULTS:

The study included 13 patients identified through NBS, 2 clinically diagnosed patients, and 2 asymptomatic siblings. All had severely reduced CD19+ B cells (< 0.1 × 109/L) at first evaluation, yet subsequent follow-up assessments indicated residual immunoglobulin production. Specific antibody responses to vaccine antigens varied, with a predominant reduction observed during infancy. Clinical outcomes were favorable with IgG substitution. Two patients successfully discontinued substitution therapy without developing susceptibility to infections and while maintaining immunoglobulin levels. The pooled incidence of homozygous or compound heterozygous pathogenic IGLL1 variants identified by NBS in Austria, Czechia, and Switzerland was 1.3100,000, almost double of X-linked agammaglobulinemia.

CONCLUSION:

B-cell deficiency resulting from IGLL1 variants appears to be more prevalent than initially believed. Despite markedly low B-cell counts, the clinical course in some patients may be milder than reported in the literature so far.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2024 Tipo de documento: Article